• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Koselugo (selumetinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Koselugo (selumetinib)

  • Profile

Profile

Contact Information

Contact: AstraZeneca
Website: https://www.koselugo.com/

Currently Enrolling Trials

    Show More

    General Information

    Koselugo (selumetinib) is a kinase inhibitor. 

    Koselugo is specifically indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.

    Koselugo is supplied as a capsule for oral administration. The recommended dosage of Koselugo is 25 mg/m2 orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity. Please see drug label for the recommended dose of Koselugo based on body surface area (BSA). Take Koselugo on an empty stomach. Do not consume food 2 hours before each dose or 1 hour after each dose. Swallow Koselugo capsules whole with water. Do not chew, dissolve or open capsule. Do not administer to patients who are unable to swallow a whole capsule. Do not take a missed dose of Koselugo unless it is more than 6 hours until the next scheduled dose. If vomiting occurs after administration, do not take an additional dose, but continue with the next scheduled dose.

    Mechansim of Action

    Kolseugo (selumetinib) is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers.

    Side Effects

    Adverse effects associated with the use of Koselugo may include, but are not limited to, the following:

    • vomiting
    • rash
    • abdominal pain
    • diarrhea
    • nausea
    • dry skin
    • fatigue
    • musculoskeletal pain
    • pyrexia
    • acneiform rash
    • stomatitis
    • headache
    • paronychia
    • pruritus

    Clinical Trial Results

    The FDA approval of Koselugo was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase II SPRINT Stratum 1 trial coordinated by the NCI’s Center for Cancer Research, Pediatric Oncology Branch. The an open-label, multicenter, single arm trial enrolled patients with NF1 with inoperable plexiform neurofibroma (PN), defined as a PN that could not be completely removed without risk for substantial morbidity due to encasement of, or close proximity to, vital structures, invasiveness, or high vascularity of the PN. Patients were also required to have significant morbidity related to the target PN. A total of 50 pediatric patients received Koselugo. The median age was 10.2 years.  Patients received Koselugo 25 mg/m2 orally twice daily until disease progression or unacceptable toxicity. Results showed an overall response rate (ORR) of 66% (33 of 50 patients, confirmed partial response). ORR is defined as the percentage of patients with confirmed complete or partial response of at least 20% reduction in tumor volume.

    Approval Date: 2020-04-01
    Company Name: AstraZeneca
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing